94 related articles for article (PubMed ID: 32056048)
1. Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells.
Li X; Zhang W; Shu Y; Huo R; Zheng C; Qi Q; Fu P; Sun J; Wang Y; Wang Y; Lu J; Zhao X; Yin G; Wang Q; Hong J
Sci Rep; 2024 Jul; 14(1):15331. PubMed ID: 38961200
[TBL] [Abstract][Full Text] [Related]
2. Destabilizing single chain major histocompatibility complex class I protein for repurposed enterokinase proteolysis.
Lim J
Sci Rep; 2020 Sep; 10(1):14897. PubMed ID: 32913247
[TBL] [Abstract][Full Text] [Related]
3. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities.
Wang J; Kang G; Lu H; de Marco A; Yuan H; Feng Z; Gao M; Wang X; Wang H; Zhang X; Wang Y; Zhang M; Wang P; Feng Y; Liu Z; Cao X; Huang H
Clin Transl Med; 2024 Mar; 14(3):e1636. PubMed ID: 38533646
[TBL] [Abstract][Full Text] [Related]
4. An anti-CTLA-4 heavy chain-only antibody with enhanced T
Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889
[TBL] [Abstract][Full Text] [Related]
5. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease.
Hu X; Fan J; Ma Q; Han L; Cao Z; Xu C; Luan J; Jing G; Nan Y; Wu T; Zhang Y; Wang H; Zhang Y; Ju D
J Nanobiotechnology; 2022 May; 20(1):237. PubMed ID: 35590366
[TBL] [Abstract][Full Text] [Related]
6. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.
Wang J; Kang G; Yuan H; Cao X; Huang H; de Marco A
Front Immunol; 2021; 12():838082. PubMed ID: 35116045
[TBL] [Abstract][Full Text] [Related]
7. Exploring cellular biochemistry with nanobodies.
Cheloha RW; Harmand TJ; Wijne C; Schwartz TU; Ploegh HL
J Biol Chem; 2020 Nov; 295(45):15307-15327. PubMed ID: 32868455
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
9. [Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].
Wallemacq C
Rev Med Liege; 2017 Nov; 72(11):505-512. PubMed ID: 29171950
[TBL] [Abstract][Full Text] [Related]
10. The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats.
Li X; Wang M; Zhang X; Liu C; Xiang H; Huang M; Ma Y; Gao X; Jiang L; Liu X; Li B; Hou Y; Zhang X; Yang S; Yang N
Clin Transl Med; 2020 Feb; 9(1):16. PubMed ID: 32056048
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a camelid derived antibody targeting a linear epitope in the hinge domain of human PCSK9 protein.
Li X; Hong J; Gao X; Wang M; Yang N
Sci Rep; 2022 Jul; 12(1):12211. PubMed ID: 35842473
[TBL] [Abstract][Full Text] [Related]
12. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
13. Local effects of human PCSK9 on the atherosclerotic lesion.
Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
